- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy | Clinical
FDA Approves Liso-Cel for Second-Line Treatment of R/R LBCL
June 25, 2022
The FDA has granted approval lisocabtagene maraleucel for the treatment of adult patients with large B-cell lymphoma, with specific indications for patients with relapsed or refractory disease.
Second CAR T Infusion Could Lead to New Response in B-ALL
June 18, 2022
Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.
Investigation of Novel CAR T Product, MB-106, in Various R/R B-Cell Malignancies
June 16, 2022
In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed his research of MB-106 as treatment for patients with relapsed or refractory B-non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Understanding CAR T-Cell Therapy Utilization Patterns in the Community Oncology Setting
June 08, 2022
In an interview with Targeted Oncology™, Bruce Feinberg, DO, discussed the use of CAR T-cell therapy in the community oncology setting, the challenges oncologist face, and the next wave of innovation to improve CAR T-cell administration for patients.
Durable Response Elicited With CLDN18.2-Directed CAR T-cell Therapy in Gastrointestinal Cancers
June 05, 2022
Treatment with a Claudin18.2–specific chimeric antigen receptor T-cell therapy has demonstrated either a response or stable disease in patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma.
Community Providers Face Hurdles With CAR T-Cell Therapy Referrals and In-Office Infusion
June 03, 2022
Few community practices are performing in-office infusions on CAR T-cell therapy, but due to interest from 20% of them, experts recommend stakeholder alignment to address the concerns of the oncology population.
Blocking TIGIT May Help With Dipping Remission Rates in NHL After CAR T-Cell Therapy
May 19, 2022
In preclinical study, researchers have identifies anti-TIGIT therapy as a potentially effective strategy for improving remission rates in patients with non-Hodgkin lymphoma after chimeric antigen receptor T-cell therapy.
High-Dose Anakinra Shows Promise in Treating CRS/ICANS Post CAR T-Cell Therapy
May 18, 2022
In an interview with Targeted Oncology, Nicolas Gazeau, further discusses his analysis of anakinra when administered at 2 different dose regimens for patients with refractory CRS/ICANS after CAR T-cell therapy.
First Patient Dosed in IMAGINE Trial Evaluating MT-101 in Patients With PTCL
May 13, 2022
Investigators of the phase 1/2 IMAGINE study, evaluating MT-101 in patients with refractory or relapsed peripheral T-cell lymphoma, have dosed its first patient.
Discussing the Use of CAR T Cells in Solid Tumors
May 11, 2022
Steven M. Albelda, MD, discusses the limited successes of CAR T cells in solid tumors.